Healthcare / Diagnostics & ResearchBSE
$6.06
+0.06 (+1.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 19%
FCF escenarios
weak_data · normalized FCF $2.5M · quality 41.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$63M
P/E
N/A
•EV/EBITDA
4.4x
↓ROE
-0.2%
↓Gross Margin
81.9%
↑Debt/Equity
0.30
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-25.3%
FCF CAGR
-10.8%
FCF margin
3.8%
FCF / Net income
-6.85x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $66.3M · net income $-372000.0 · FCF $2.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $66.3M | $66.3M | $131.2M | $119.2M | $159.3M |
| Net Income | $-372000.00 | $-372000.00 | $41.5M | $10.6M | $43.7M |
| EBITDA | $11.8M | $11.8M | $67.4M | $25.1M | $65.3M |
| EPS | -0.04 | -0.04 | 4.01 | 1.03 | 4.23 |
| Gross Margin | 81.9% | 81.9% | 86.6% | 76.8% | 82.3% |
| Operating Margin | 6.9% | 6.9% | 43.2% | 11.3% | 35.8% |
| Net Margin | -0.6% | -0.6% | 31.6% | 8.9% | 27.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.30 | 0.30 | 0.25 | 0.30 | 0.32 |
| Cash Flow | |||||
| Free Cash Flow | $2.5M | $2.5M | $-2.9M | $5.9M | $3.6M |
| Returns | |||||
| ROE | -0.2% | -0.2% | 21.6% | 7.0% | 31.2% |
| Valuation | |||||
| EV/EBITDA | 4.37 | 4.37 | — | — | — |
| P/B | 0.33 | 0.33 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | -49.5% | -49.5% | 10.0% | -25.1% | — |
| EPS Growth | -101.0% | -101.0% | 289.3% | -75.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-62.9%
Start / end P/E
n/dx → n/dx
EPS bridge
4.01 → -0.04
Residual
-62.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.